Last reviewed · How we verify
Staidson (Beijing) Biopharmaceuticals Co., Ltd — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
3 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| BDB-001 injection | BDB-001 injection | phase 3 | Unknown | Oncology | ||
| STSA-1002 injection | STSA-1002 injection | phase 3 | PD-1 inhibitor | PD-1 | Oncology | |
| STSP-0601 for Injection | STSP-0601 for Injection | phase 3 | Interferon alpha fusion protein | Interferon alpha receptor (IFNAR) | Virology/Immunology |
Therapeutic area mix
- Oncology · 2
- Virology/Immunology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- ASLAN Pharmaceuticals · 1 shared drug class
- ATGC Co., Ltd. · 1 shared drug class
- Addpharma Inc. · 1 shared drug class
- Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
- Akeso · 1 shared drug class
- Amgen · 1 shared drug class
- Asahi Kasei Pharma Corporation · 1 shared drug class
- 3D Medicines (Sichuan) Co., Ltd. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Staidson (Beijing) Biopharmaceuticals Co., Ltd:
- Staidson (Beijing) Biopharmaceuticals Co., Ltd pipeline updates — RSS
- Staidson (Beijing) Biopharmaceuticals Co., Ltd pipeline updates — Atom
- Staidson (Beijing) Biopharmaceuticals Co., Ltd pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Staidson (Beijing) Biopharmaceuticals Co., Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/staidson-beijing-biopharmaceuticals-co-ltd. Accessed 2026-05-18.